High-throughput screening has become a mainstay of small-molecule probe and early drug discovery. The question of how to build and evolve efficient screening collections systematically for cellbased and biochemical screening is still unresolved. It is often assumed that chemical structure diversity leads to diverse biological performance of a library. Here, we confirm earlier results showing that this inference is not always valid and suggest instead using biological measurement diversity derived from multiplexed profiling in the construction of libraries with diverse assay performance patterns for cell-based screens. Rather than using results from tens or hundreds of completed assays, which is resource intensive and not easily extensible, we use high-dimensional image-based cell morphology and gene expression profiles. We piloted this approach using over 30,000 compounds. We show that small-molecule profiling can be used to select compound sets with high rates of activity and diverse biological performance.chemical diversity | biological performance diversity | biological activity | chemical similarity P rofiling small molecules based on multiple biological activity measurements can illuminate mechanisms of action by comparing profiles with compounds whose mechanisms of action are known (1-5). Here, we describe a previously unidentified use of small-molecule profiling-enabling the creation of activityenriched and performance-diverse compound libraries for smallmolecule probe and drug discovery.Biochemical and cell-based high-throughput screening (HTS) is routinely used to discover novel bioactive molecules through unbiased testing of up to several million compounds per screen (6). However, despite ongoing advances in throughput, compound libraries will always represent only a small fraction of all relevant compounds theoretically accessible through chemical synthesis (a concept often referred to as "chemical space") (7). Library composition therefore presents a strong source of bias and potential limitation for any screening endeavor.There is little dissent about the notion that a good screening collection should yield many high-quality hits for a wide range of biological targets or phenotypes. In other words, it should be enriched for bioactive compounds and have high biological performance diversity. A high percentage of compounds lacking any activity will contribute to high cost and low performance of a high-throughput screen. A practical example is a compound collection containing a high percentage of compounds that fail to penetrate cell membranes-such a library will be unlikely to perform effectively in a cell-based HTS exploring an intracellular process. Similarly, a screening collection of compounds with highly redundant biological activities will be less efficient than an equally sized library with diverse performance (Fig. 1). A systematic path to reach these goals, however, remains elusive. One common practice is analyzing structural features of compounds to maximize chemical structural diversity. Ho...

There are no effective medical treatments for WHO grade III (anaplastic) meningioma. Patients with this high-grade malignancy have a median survival of less than two years. Therapeutics that modulate the mechanisms that inhibit local immune responses in the tumor microenvironment are showing significant and durable clinical responses in patients with treatment refractory high-grade tumors. We examined the immune infiltrate of 291 meningiomas including WHO grade I-III meningiomas using immunohistochemistry and we examined the expression of PD-L1 mRNA by RNAscope in situ hybridization and PD-L1 protein by immunohistochemistry. In meningioma, the tumor infiltrating lymphocytes are predominantly T cells. In anaplastic meningioma, there is a sharp decrease in the number of T cells, including the numbers of CD4+ and CD8+ T cells and cells expressing PD-1 and there is also an increase in the number of FOXP3 expressing immunoregulatory (Treg) cells. PD-L1 expression is increased in anaplastic meningioma – both mRNA and protein. Using patient derived meningioma cell, we confirm that PD-L1 is expressed in meningioma cells themselves, and not solely in infiltrating immune cells. This work indicates that high-grade meningioma harbor an immunosuppressive tumor microenviroment and that increased Treg cells and elevated PD-L1 may contribute to the aggressive phenotype of these tumors.

Cardiac tissue engineering requires finely-tuned manipulation of the extracellular matrix (ECM) microenvironment to optimize internal myocardial organization. The myocyte nucleus is mechanically connected to the cell membrane via cytoskeletal elements, making it a target for the cellular response to perturbation of the ECM. However, the role of ECM spatial configuration and myocyte shape on nuclear location and morphology is unknown. In this study, printed ECM proteins were used to configure the geometry of cultured neonatal rat ventricular myocytes. Engineered one- and two-dimensional tissue constructs and single-myocyte islands were assayed using live fluorescence imaging to examine nuclear position, morphology and motion as a function of the imposed ECM geometry during diastolic relaxation and systolic contraction. Image analysis showed that anisotropic tissue constructs cultured on microfabricated ECM lines possessed a high degree of nuclear alignment similar to that found in vivo; nuclei in isotropic tissues were polymorphic in shape with an apparently random orientation. Nuclear eccentricity was also increased for the anisotropic tissues, suggesting that intracellular forces deform the nucleus as the cell is spatially confined. During systole, nuclei experienced increasing spatial confinement in magnitude and direction of displacement as tissue anisotropy increased, yielding anisotropic deformation. Thus, the nature of nuclear displacement and deformation during systole appears to rely on a combination of the passive myofibril spatial organization and the active stress fields induced by contraction. Such findings have implications in understanding the genomic consequences and functional response of cardiac myocytes to their ECM surroundings under conditions of disease.

No abstract